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Heparin, a glycosaminoglycan (GAG), has both anti-inflammatory and anti-coagulant
properties. The clinical use of heparin against inflammation, however, has been limited
by concerns about increased bleeding. While the anti-coagulant activity of heparin is
well understood, its anti-inflammatory properties are less so. Heparin is known to bind
to certain cytokines, including chemokines, small proteins which mediate inflammation
through their control of leukocyte migration and activation. Molecules which can
interrupt the chemokine-GAG interaction without inhibiting coagulation could therefore,
represent a new class of anti-inflammatory agents. In the present study, two approaches
were undertaken, both focusing on the heparin-chemokine relationship. In the first, a
structure based strategy was used: after an initial screening of potential small molecule
binders using protein NMR on a target chemokine, binding molecules were optimized
through structure-based design. In the second approach, commercially available short
oligosaccharides were polysulfated. In vitro, these molecules prevented chemokine-GAG
binding and chemokine receptor activation without disrupting coagulation. However,
in vivo, these compounds caused variable results in a murine peritoneal recruitment
assay, with a general increase of cell recruitment. In more disease specific models,
such as antigen-induced arthritis and delayed-type hypersensitivity, an overall decrease
in inflammation was noted, suggesting that the primary anti-inflammatory effect may also
involve factors beyond the chemokine system.
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INTRODUCTION
The process of inflammation involves the recruitment and acti-
vation of a wide variety of leukocytes. Chemokines are a large
family of small proteins known to mediate this process. They
activate target cells through a large family of seven transmem-
brane G-protein coupled receptors. In vivo, the situation is more
complicated, and it has been proposed that chemokines work by
producing immobilized or haptotactic gradients, which direct the
migration of cells to the sites of inflammation, both by directing
extravasation from the blood vessels and also migration through
the tissues (Rot, 1993). These gradients are formed by the interac-
tion of the chemokines with glycosaminoglycans (GAGs) (Handel
et al., 2005). Studies on specific chemokines have mapped the
binding sites of the GAGs to the chemokines, largely using hep-
arin, and closely related GAGs such as chondroitin sulfate, and
dermatin sulfate (Kuschert et al., 1998; Proudfoot et al., 2001;
Lau et al., 2004). Modified chemokines, with both reduced and
enhanced interaction between chemokines and GAGs, have been
shown to modulate inflammatory processes (Johnson et al., 2004;
Ali et al., 2005; Bedke et al., 2010; Tanino et al., 2010). Although
protein therapeutics have been very successful for several indi-
cations, orally available small molecules could be more useful
in long term therapies. Moreover, most therapeutic strategies
address extracellular protein–protein interactions or intracellu-
lar signaling pathways. We have proposed interference with the
chemokine/GAG interaction as a novel anti-inflammatory strat-
egy, and have therefore tried two methods of identifying small
molecules which can alter the chemokine-GAG interaction and
reduce inflammation.
Heparin is a highly sulfated GAG which has a wide variety of
molecular interactions. It displays promising anti-inflammatory
activities clinically in asthma (Ahmed et al., 1993, 1999), ulcer-
ative colitis (Evans et al., 1997), and burns (Iashvili et al., 1986).
Heparin, as well as other GAGs, such as heparan sulfate (HS), also
show potential as anti-cancer agents and a synthetic HS analog
PI-88, which is an inhibitor of heparanase, is currently in clinical
studies for treatment of lung cancer, liver cancer, as well as mul-
tiple myeloma and melanoma (Basche et al., 2006; Ferro et al.,
2007; Kudchadkar et al., 2008).
However, its primary clinical action is to activate anti-
thrombin III (AT III), via a conformational change, resulting in
inhibition of both thrombin and factor Xa thereby preventing
clotting. A specific pentapeptide sequence is required for this
activity. Versions of low molecular weight heparin or analogs,
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without the anti-coagulant activities, have been produced to pre-
vent erythrocyte resetting, a complication of malaria, (sevuparin,
DF-02) and are in clinical phase I (Leitgeb et al., 2011).
Compounds that lack the anti-thrombotic effect of heparin,
whilst maintaining its other activities, would be useful to fur-
ther study the beneficial properties of GAGs in inflammatory and
auto-immune diseases. We describe here two approaches to pro-
duce compounds that inhibit the chemokine activity, namely their
binding to their receptors as well as to GAGs. Compounds that
bind and neutralize chemokine ligands, as opposed to their recep-
tors have been identified for the chemokine CXCL12 (Hachet-
Haas et al., 2008; Galzi et al., 2010). We chose CCL5 as the
chemokine target due to its well documented pro-inflammatory
role in many diseases (Appay et al., 1999; Handel et al., 2005).
The availability of a three dimensional structure, and the previ-
ous mapping of the GAG binding site (Chung et al., 1995; Shaw
et al., 2004) was an important starting point for the design of spe-
cificmolecules. The first approach was a structure based approach
following identification of sulfated compounds that bind CCL5.
The second was the sulfation of small oligosaccharides following
the observation that 4-mer and 6-mer oligosaccharides inhib-
ited CCL5-induced cellular recruitment into the peritoneal cavity
(Shaw et al., 2004).
EXPERIMENTAL PROCEDURES
REAGENTS
Unless stated otherwise, all chemicals were purchased from Sigma
Aldrich. The heparins used in the assays were heparin sodium salt
from porcinemucosa (6–30 kDa; catalog number H3393) and low
molecular weight heparin (3 kDa; catalog number H3400), both
supplied by Sigma Aldrich. 15N-labeled CCL5 was prepared using
standard procedures (Chung et al., 1995).
IDENTIFICATION OF CCL5 BINDERS
An NMR-based screening approach was employed (Hajduk et al.,
1999; Parish et al., 1999) to identify a small molecule binding to
the chemokine CCL5. At concentrations required for NMR-based
screening (>100μM), CCL5 aggregates at physiological pH, and
at pH values above 4.5 most of the proton resonances are severely
broadened. Consequently, all experiments with wild-type CCL5
were performed at a pH 3.2 at 200μM in 10% (v/v) deuterated
water (D2O) and 90% (v/v) H2O, since in these conditions the
protein is essentially a monomer.
A chemically diverse library composed of 206 compounds of
low molecular weight (<350 Da) was designed for its potential
ability to interact with GAG binding sites. These molecules were
charged, and containedmultiple acid groups, such as carboxylates
and sulfonates. In addition, many of the molecules were aromatic,
to provide some hydrophobicity. The library was pooled into sets
containing five compounds and these pools mixed at 200μM,
with an equal concentration of CCL5 at 30◦C, and a heteronuclear
single quantum coherence (HSQC) spectrum recorded immedi-
ately. For pools that induced significant change in the protein
chemical shifts, a second round of screening was performed in
which each of the five compounds was added individually to
the protein solution. For those molecules that displayed clear
binding to CCL5, the dissociation constant Kd was measured by
recording a series of 15N-HSQC spectra with increasing concen-
tration of ligand. Dissociation constants were obtained by fitting
the recorded chemical shift as a function of increasing ligand
concentrations with:
δobs = δf + Lbb− f (1)
in which δobs is the observed chemical shift at each point of the
titration curve, δf is the chemical shift of the free protein and
b− f is the difference in chemical shift between free and fully
complexed protein.
STRUCTURAL DETERMINATIONOF CCL5-BINDER COMPLEXES
The crystallization conditions of CCL5 were essentially those pre-
viously described (Shaw et al., 2004). Briefly, CCL5 at 10mg/ml
in 50mM acetate buffer pH 3.5, and the various molecules were
incubated at a final concentration of the molecule of 0.1–0.5mM
(when solubility permitted) and crystallized at room temperature
by hanging drop vapor diffusion in 15% (w/v) polyethylene glycol
(PEG) 400, 50mM acetate buffer pH 4.5, and 10% (w/v) glycerol.
Crystallographic data were collected at 100K on an Enraf-Nonius
FR591 rotating anode generator equipped with Osmic MaxFlux
mirrors and a MAR345 image plate detector. All the crystals of
CCL5 belong to the orthorhombic space group P212121 with
unit cell dimensions of a = 24 Å, b = 56 Å, and c = 94 Å, and
contain a dimer of CCL5 in the asymmetric unit. Data was pro-
cessed using DENZO and SCALEPACK (Otwinowski and Minor,
1997). Rigid body, simulating annealing, positional and B-factor
refinement were performed with CNS (Brunger et al., 1998) and
model building with Coot (Emsley et al., 2010). Bulk solvent
and anisotropic B-factor corrections were applied. A number of
other molecules, similar in structure to Molecule 1 were subse-
quently studied in the hope of establishing a structure-activity
relationship (SAR), and in order to identify a promising starting
point for the optimization of the CCL5-binders. In excess of 30
compounds, essentially poly-substituted phenyl sulfonates, were
synthesized or purchased (see Figure 1A), and their binding affin-
ity for CCL5 (Kd determined by NMR), and occasionally, their
crystal structures determined (data not shown). It proved impos-
sible to crystallize CCL5 in the presence of Molecule 3, due to
the propensity of this molecule to cause precipitation of CCL5,
despite all attempts to maintain the complex in solution.
SYNTHESIS OF THE CHIMERA
Molecule 3: 5-[(11-{[(3-carboxy-4hydroxyphenyl) sulfonyl]
amino} undecanoyl)amino]-2-hydroxy-3-sulfobenzoic acid.
The amide bond was formed with 1 equivalent of Molecule 2,
1.5 equivalents of N-Boc aminoacid, 1.5 equivalents of
N,N′-diisopropylcarbodiimide (DIC), and 2.5 equivalents
of triethylamine (Et3N) in dichloromethane (DCM) overnight.
A solution of 11-[(tert-butoxycarbonyl)amino]undecanoic acid
(362mg, 1.2mmol) and DIC (151mg, 1.2mmol) in DCM
was stirred at room temperature for 1 h. 5-amino-2-hydroxy-
3-sulfobenzoic acid (233mg, 1mmol) and ET3N (202mg,
2mmol) were added, and the reaction mixture stirred overnight.
Methanol and Amberlyst 15 were added and the reaction
mixture stirred at room temperature for an additional 2 h.
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FIGURE 1 | Structure of the compounds. (A) CCL5 binders. All the Kd
values were determined by protein NMR. In the cases where the Kd
could not be determined, either due to the low affinity of the compound,
or due to precipitation of the complex, are indicated as not determined
(n.d.). The molecules whose structure in complex with CCL5 was
determined are indicated, including the pockets occupied by the molecule.
Those molecules whose structure was attempted, but failed to crystallize
are also described, while those for which no attempt to determined the
co-crystal structure are indicated as not determined (n.d.). (B) The
carbohydrates used for sulfation.
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The solution was filtered and concentrated, produc-
ing 5-({11-[(tert-butoxycarbonyl)amino]undecanoyl}amino)-2-
hydroxy-3-sulfobenzoic acid at 84.8% purity by reversed-phase
HPLC.
A solution of 5-({11-[(tert-butoxycarbonyl)amino]
undecanoyl}amino)-2-hydroxy-3-sulfobenzoic acid in DCM/
trifluoroacetic acid (9/1) was stirred at room temperature
overnight. The solvents were removed to produce 5-[(11-
aminoundecanoyl)amino]-2-hydroxy-3-sulfobenzoic acid as
trifluoroacetate salt at 97.7% purity with an overall yield of 60%
of the two steps (340mg).
After removal of the Boc group, the sulfonamide
bond was formed in dimethylformamide (DMF) with 10
equivalents of Et3N under vigorous stirring. A solution
of 5-[(11-aminoundecanoyl)amino]-2-hydroxy-3-sulfobenzoic
acid (250mg, 0.3mmol), 5-chlorosulfonyl-2-hydroxybenzoic
acid (142mg, 0.5mmol) and triethylamine (304mg, 3mmol)
in DMF was stirred at room temperature for 1 h. Methanol and
Amberlyst 15 were added and the reaction mixture was stirred at
room temperature for an additional 2 h. The solution was filtered
and concentrated. The crude product was purified by preparative
reversed-phase HPLC to produce the title compound at 50%
yield (87mg) and 100% purity.
SYNTHESIS OF SULFATED CARBOHYDRATES
The sulfation of commercially available sugars was performed
as described earlier (Parish et al., 1999). Briefly, 100mg of
the starting material, namely Maltohexaose (MHx), Nistose
(Nis) (1-O-(1-O-β-D-Fructofuranosyl-β-D-fructofuranosyl)-β-
D-fructofuranosyl α-D-glucopyranoside, or Stachyose (Stach)
(β-D-Fructofuranosyl-O-α-D-galactopyranosyl-(1→6)-O-α-D-
galactopyranosyl -(1→6)-α- D-glucopyranoside (Figure 1B),
were dissolved in 400ml DMF and 600ml pyridine, and 40 equiv-
alents of sulfur trioxide-pyridine complex were added (642mg
for MHx or 955mg for Nis and Stach). The reaction was stirred at
80◦C for 3 h. The supernatant was decanted, the sticky yellowish
residue was washed three times with methanol (MeOH), and then
dissolved in 5ml 0.1M Tris/HCl buffer, pH 8.5. The resulting
solution was extracted five times with 10ml of ether (Et2O) to
remove residual pyridine. The solution was then dialyzed twice
against 5 L 20mM Tris/HCl buffer pH 7.5, twice against 5 L
200mM NaCl to make the sodium salt of the product and sub-
sequently twice against 5 L double distilled water (ddH2O), using
cellulose ester dialysis tubes with MWCO at 500Da (Spectra/Por
Biotech). The resulting persulfated oligosaccharides, namely per-
sulfated MHx (MHxS), persulfated Nis (NisS), and persulfated
Stach (StachS) were dried using a speed vacuum.
IMMOBILIZED HEPARIN COMPETITION BINDING ASSAY
Competition experiments were performed as described else-
where (Severin et al., 2010). Briefly, heparin-Sepharose beads
(Sepharose beads or binding buffer as a background control) and
increasing amounts of antagonist were added to each well of a
96 well filter plate. [125I]-CCL5, was added last, to reach a final
concentration of 0.05 nM. The plates were incubated on a shaker
at room temperature for 4 h. Each experiment was performed in
triplicate, and the results are given as the mean of the three assays.
EQUILIBRIUM COMPETITION RECEPTOR BINDING ASSAYS
The assays were carried out on membranes from CHO transfec-
tants expressing CCR1 or CCR5, as described previously (Severin
et al., 2010). Briefly, serial dilutions of the compounds were pre-
pared in binding buffer (50mM TrisHCl, pH 7.2, containing
1mM CaCl2, 5mM MgCl2, and 0.5% BSA). Equal volumes of
membrane preparation at 80μg/ml and scintillation proximity
assay (SPA) beads were mixed before adding them to a 96 well
filter plate, giving a final membrane concentration in the assay
of 20μg/ml. 125I labeled chemokines were dissolved in bind-
ing buffer at a concentration of 0.4 nM. The assay was started
by the addition of 25μL [125I]-CCL5 to give a concentration of
0.1 nM, in a final assay volume of 100μL. The plates were incu-
bated for 4 h. Radioactivity was counted with a beta counter for
1min/well and the data analyzed using Graphpad Prism software.
The radioligand was stored at −20◦C and was used until the cpm
of bound chemokine was ≥ 300 cpm.
ANTI-COAGULATION ASSAY
Activated Partial Thromboplastin Time (APTT) assays were per-
formed by GlycoMar. 10mg/ml stock solutions of NisS, StachS,
and MHxS, were prepared using dH2O and stored at −20◦C
until use. Samples were tested at 1mg/ml. All further dilu-
tions were in dH2O. Prior to each assay, a calibration curve
of heparin ranging from 0 to 10 IU/ml was prepared using 5th
International Standard Heparin. (GlycoMar ID:92, batch 97/578,
Expiry 21SEP10). Fresh human blood from healthy human blood
donors was collected into S-Monovette Coagulation tubes from
Sarstedt. Nine parts of freshly drawn venous blood were col-
lected into one part trisodium citrate (0.106M). Plasma was
obtained by centrifugation at 1500× g for 10min. Each of the
carbohydrate samples was diluted and tested at 1mg/ml in the
first instance. MHxS was subsequently tested at 0.1mg/ml to be
within the time frame of the standard curve. The APTT assay
was run on an ACL 9000 Coagulation Analyzer. The coagula-
tion time of HemosIL Normal Control (cat no. 0020003110)
was checked. Samples, standards and controls were mixed 1:10
with citrated plasma in a test tube, loaded into the ACL
9000 carousel and analyzed using the extended APTT run
program.
In vivo EXPERIMENTATION: ANIMALWELFARE
All experimental protocols were carried out using international
standards for animal experimentation and approved by the
local authority where the experiment took place. More specifi-
cally, the mBSA-induced arthritis model was subjected to eval-
uation and approval by the animal ethics committee of the
Universidade Federal de Minas Gerais (www.ufmg.br/bioetica/
cetea/). As for the delayed-type hypersensitivity and the peri-
toneal recruitment models, all applied procedures were approved
by and respected the best practices for animal studies promoted
by the Animal Experimentation Domain of the General Health
Direction of the Republic and Canton of Geneva (Republique et
Canton de Genève, Direction Générale de la Santé, Domaine de
l’expérimentation animale). In general, animals were acclimatized
for at least 1 week prior to experimentation, maintained at 12/12 h
light/dark cycle and given food and water ad libitum. The mouse
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strain that was used and its origin is referred to in the description
of each model below.
All compounds were tested for endotoxin content prior to
administration.
PERITONEAL RECRUITMENT
CCL5-induced peritoneal recruitment was performed as
described (Johnson et al., 2004). Thioglycollate-induced cellular
recruitment was mediated by the administration of 40mL/kg of
3% thioglycollate i.p. in 7- to 8-week-old female C3H/Hen mice
(JANVIER). Sham mice were injected with 40mL/kg of NaCl
(0.9%, LPS free). Saline (vehicle, control group) or Maltohexaose
Sulfate at doses ranging from 1 to 0.01mg/kg diluted in a volume
ratio of 10mL/kg and were administered i.p. 30min before the
thioglycollate stimulus, and 24 h later. An additional group of
mice was injected with a single dose of 3mg/kg dexamethasone
1 h before challenge as a reference control. Mice were sacrificed
48 h post-thioglycollate injection, the peritoneal cavity was
washed twice with 5mL of 0.5M EDTA solution in PDB, pH 7.4.
The peritoneal lavage fluid was centrifuged and resuspended in
1mL of the solution and recruited cells were counted with a cell
counter (Beckman-Coulter, ACT5Diff AD32097).
DELAYED-TYPE HYPERSENSITIVITY (DTH) MODEL
Female BALB/c mice were immunized with 2 × 106 sheep red
blood cells (SRBC) by subcutaneous route (s.c.) at the base of
the tail. Five days later mice were challenged with an s.c. injec-
tion of 2 × 106 SRBC into the softpaw of the left hindpaw. The
paw thickness was measured 21 h later and the difference calcu-
lated based on values obtained before challenge. MHxS, NisS, and
StachS were injected s.c. at a dose of 10mg/kg, 30min before and
8 h after challenge. Vehicle was 0.02% BSA diluted in PBS. The
reference compound, dexamethasone, was diluted in saline and
administered by oral gavage 30min before challenge. Group sizes
were 6 for sham and 8 for all other groups.
ANTIGEN-INDUCED ARTHRITIS (AIA) MODEL
Induction of disease was performed by injection of 10μg methy-
lated bovine serum albumin (mBSA) as a 10μL injection into
the synovial cavity. Test compounds, at a total dose of 50μg were
injected in a total volume of 200μL subcutaneously immediately
after mBSA administration. Group sizes were 4–6 animals. Total
leukocytes (A), neutrophils (B), and mononuclear cells (C) in the
synovial cavity were enumerated 24 h after mBSA injection (Sachs
et al., 2011).
STATISTICAL ANALYSIS
The results from the peritoneal recruitment models-induced
by CCL5, thioglycollate, the DTH model, and the knee cav-
ity recruitment were analyzed by One-Way-ANOVA followed by
Newmann-Keuls multiple comparisons test.
RESULTS
IDENTIFICATION OF CCL5 BINDERS
15 compounds of the 206 compounds screened elicited a change
in the protein chemical shifts, but only three of these, Molecules
1, 8, and 10 were confirmed to be selectively binding to CCL5;
the most striking beingMolecule 1 (See Figure 1A). The chemical
shift perturbations observed for the amide resonances of Thr43,
Arg44, and Lys45 in the presence of Molecule 1 suggest that the
compound binds in the 40s loop of CCL5.
ANALYSIS OF THE BINDING MODE OF CCL5 BINDERS IDENTIFIED BY
NMR AND X-RAY CRYSTALLOGRAPHY
The structure of Molecule 1 complexed to CCL5 was obtained
at a resolution of 1.8 Å (see Figure 2A). The complex crystal-
lized in the same crystal form as the wild-type protein, with
two monomers (called monomer A and B) in the asymmetric
unit. With the exception of the extreme N- and C-termini, the
protein structure is essentially the same as that of the wild-type
protein. However, the analysis of the structure revealed that the
two copies of Molecule 1 in the structure were not identical, and
that one of the two molecules was actually a minor contami-
nant (<0.5%) of the original batch of Molecule 1. Molecule 1
was found in close proximity to a surface loop composed of
residues Ser31A-Gly32A-Lys33 (hereafter called the 30s pocket;
see Figure 2A). The sulfonate group of Molecule 1 forms two
hydrogen bonds with the main chain nitrogen of Gly32A (3.0 Å
and 3.3 Å), while the carboxylate group of Molecule 1 forms a
hydrogen bond with the Lys33A sidechain (2.8 Å). The hydroxyl
group of Molecule 1 forms a hydrogen bond with a crystallo-
graphic symmetry-related monomer of CCL5 to the main chain
carbonyl group of Pro18A (3.2 Å). Molecule 2 (see Figure 1A)
is the minor contaminant identified in the crystal structure, and
binds to a pocket onmonomer A composed of residues Thr43A to
Arg47A (hereafter called the 40s pocket; see Figure 2B). The sul-
fonate group of Molecule 2 forms a hydrogen bond with Thr43A
(2.5 Å), and a relatively weak one with Arg47A side chain (3.5 Å).
The hydroxyl group of Molecule 2 forms a hydrogen bond with
Thr43A (3.1 Å). While in the same asymmetric unit, Molecules
1 and 2 are fairly distant from one another (∼25 Å), they are rela-
tively close when a crystallographic symmetry-related molecule
of CCL5 is included (∼10 Å). It is this proximity that sug-
gested that the linking of Molecules 1 and 2 might engender
a molecule with much higher potency than either of the indi-
vidual molecules, since they may be acting as two-independent
GAG monomers. Consequently, attempts were made to optimize
Molecules 1 and 2 for their respective pockets, and subsequently
to link them.
NumerousMolecule 1 or 2 analogs were synthesized and tested
for their affinity to CCL5, and the crystal structures of several of
them were determined, in order to identify their binding site (see
Figure 1A). Many of the synthesized molecules bound to either
the 30s loop, or the 40s pocket, as expected. Some of the new
molecules bound to both sites (data not shown). The analysis of
the SAR of the analogs of Molecule 1 suggested that the pres-
ence and position of the sulfonate group is absolutely required
for binding to the 30s pocket, but that this sulfonate group may
be substituted to produce various sulfonyl groups. The study of
the SAR of Molecule 2 revealed that the substitution pattern of
Molecule 2 cannot be varied, but that substitution at the para
position of the hydroxyl group is tolerated. The determination
of the relative affinities of these Molecules 1 and 2 analogs was
complicated by the fact that themore potent compounds-induced
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FIGURE 2 | Crystallographic structure of CCL5 (A) with Molecules
1 and 2 bound. The contents of the asymmetric unit are displayed,
showing the distance between the two molecules binding to the
protein. (B) binding site of Molecules 1 and 2. The binding pocket for
Molecule 2 is the same as in panel 2A, but Molecule 1, and its
associated binding pocket are from a symmetry-related dimer. The
distance between the two molecules in thus only 10 Å, compared to
over 30 Å in panel 2A.
precipitation of CCL5, rendering the affinity measurement by
NMR impossible.
In a further attempt to increase the potency of the individual
binders identified by NMR screening, the two Molecules 1 and 2
were chemically linked together in order to produce a chimera,
Molecule 3. After several attempts, comprising liquid- and solid-
phase strategies the amide bond formation was achieved using the
Boc-protected amino acid in the presence of DIC using Et3N as
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the base. The overall synthesis was hampered by the relatively low
solubility of the final product, giving an overall yield of 30%.
INHIBITION OF BINDING BY THE CCL5 BINDERS
A study of the relative affinity of Molecule 1 toward CCL5 and
heparin molecules was first evaluated by competition experi-
ments in which CCL5, immobilized on heparin beads, was com-
peted off the beads by increasing concentrations of Molecule 1.
In this experiment, an IC50 of 0.32mM for Molecule 1 was
observed (Figure 3A). Despite this low IC50, Molecule 1 is the
first small molecule identified capable of disrupting the inter-
action between heparin and CCL5. Since the principal GAG
binding motif of CCL5, the BBXB motif on the 40s loop, plays
a role in binding to CCR1, we determined the capacity of
Molecule 1 to inhibit the binding of the chemokine CCL5 to
its receptors CCR1 and CCR5 using equilibrium competition
binding with a SPA-based assay. Molecule 1 was in fact more
potent in this assay, as it competed 125CCL5 for binding to
CHO/CCR1 transfectants with an IC50 value of 6.7μM, but had
no effect on CCL5 binding to CCR5, consistent with the fact
that the GAG binding motifs of CCL5 are distinct from those
for CCR5 (Figure 3B). In order to evaluate if Molecule 1 could
be a general CCR1 antagonist, the same experiment was per-
formed with CCL3 as the ligand; however, no competition of
CCL3 to its receptors CCR1 and CCR5 was observed (data not
shown). We conclude that Molecule 1 is selective for CCL5 bind-
ing to CCR1. However, contrary to our predictions, Molecule 3
demonstrated no increased potency as it demonstrated an IC50
value of 2.5μM for inhibition of binding to CCR1 (Table 1,
Figure 3B).
INHIBITION OF BINDING BY THE SULFATED GAG ANALOGS
As the sulfated oligosaccharides are structurally closely related to
heparin fragments, we tested their ability to inhibit the chemokine
heparin interaction. Using the CCL5 heparin bead binding assay,
we detected similar IC50 values for all three sulfated oligosaccha-
rides with MHxS being the most potent (Table 1 and Figure 3C)
and all were superior compared to the value obtained for fraction-
ated 3 kDa (H3400) heparin.
We again used the SPA binding assay to test the inhibition of
receptor binding by the sulfated GAG analogs, in comparison to
3 kDa heparin (H3400). All three of the sulfated compounds were
potent inhibitors of CCL5 binding to both CCR1 and CCR5, in
contrast to the synthetic molecules such as Molecule 1 (Table 1
and Figures 3D,E).
Table 1 | IC50 values (µM) of GAG analogs for the inhibition of CCL5
binding to heparin and CCL5 receptors.
Heparin CCR1 CCR5
CCL5 BINDERS
Molecule 1 320 6.7 n.a.
Molecule 2 nd nd nd
Molecule 3 nd 2.5 nd
PERSULFATED OLIGOSACCHARIDES
NisS 5.89 ± 0.04 1.92 ± 1.31 0.18± 0.02
StachS 18.6 ± 4.34 1.47 ± 0.89 0.20 ± 0.01
MHxS 1.27 ± 0.67 0.49 ± 0.31 0.03 ± 0.03
3 kDa heparin 22.6 ± 3.25 1.58 ± 0.63 0.48 ± 0.67
nd, not determined; n.a., no activity.
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FIGURE 3 | Inhibition of CCL5 binding by GAG analogs. Inhibition of CCL5
binding to heparin was measured by the ability to compete for 125I-CCL5
binding to heparin beads by Molecule 1 (A) and persulfated oligosaccharides
(C). Inhibition of CCL5 binding to its receptors was determined by
competition equilibrium binding assays using membranes from transfectants
expressing CCR1 (B) and (D) or CCR5 (E) by persulfated oligosaccharides.
Legend: • Molecule 1;  Molecule 3;  Molecule 1 on CCR5; MHxS;
 StachS;  NisS; ©, 3 kDa (H3400) heparin.
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ANTI-COAGULATION ASSAY
We performed APTT assays to determine the anticoagulant prop-
erties of the tetrasaccharides NisS and StachS and the hexasac-
charide MHxS in comparison to heparin and heparin-derived
tetrasaccharide and hexasaccharide pools (dp4 and dp6, respec-
tively). No anti-coagulation activity was found for the dp4 and
dp6, whilst the anticoagulant potency was 12-fold reduced for
MHxS and 15-fold reduced for NisS and StachS compared to
heparin (Table 2).
THIOGLYCOLLATE-INDUCED PERITONEAL RECRUITMENT ASSAYS
In order to determine, if the inhibition of heparin and
receptor binding produces an anti-inflammatory effect, we
Table 2 | Anti-coagulation activity.
Compound Coagulation time (IU/mg)
Heparin 152.9±26.2
dp4 0.97±0.30
dp6 2.03±0.65
NisS 6.87±3.22
StachS 6.90±2.69
MHxS 11.87±3.07
used a simple in vivo model of inflammation. The model
we chose was thioglycollate-induced peritonitis. As shown in
Figure 4, despite its lack of potency in the in vitro assays,
Molecule 1 inhibited cell recruitment to the peritoneum in a
dose dependent manner. However, when we tested Molecule 3
designed to bind to two separate sites of CCL5, we observed
an enhancement of cell recruitment to the peritoneal cavity
(Figure 4B).
The sulfated GAGs also displayed increased recruitment in
this peritonitis assay. Again, rather than inhibit cell recruit-
ment the compounds enhanced recruitment, albeit moderately,
as demonstrated for MHxS (Figure 4D). In contrast to previ-
ously published results for CCL5 mediated peritonitis (Shaw
et al., 2004), heparin showed a small tendency to enhance
recruitment in this model (Figure 4C). We hypothesized that
endogenous cells in the peritoneal cavity might be released upon
injection of heparin and the compounds, thus enhancing the
number of cells in the lavage, which was incorrectly interpreted
as enhanced recruitment. We therefore performed peritoneal
washes with solutions containing either heparin or the com-
pounds. We found that neither heparin nor the GAG-related
compounds increased the number of cells in these washes com-
pared to a peritoneal wash with PBS or PBS/EDTA (data not
shown).
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FIGURE 4 | Inhibition of peritoneal cellular recruitment. Cellular
recruitment into the peritoneal cavity was induced by CCL5 (A) and
(B) and inhibited by different doses of CCL5 binders administered
30min prior to the CCL5 administration. Cellular recruitment into
the peritoneal cavity was induced by thioglycollate (C) and (D) and
treated by increasing doses of heparin (C) and MHxS (D) using
dexamethasone as a positive control. The statistical differences versus the
control groups (CCL5 alone-treated mice in A and B; or Thioglycollate
alone-treated mice in C and D) are shown whenever present and indicated
by ∗P < 0.05; ∗∗P < 0.01 or ∗∗∗P < 0.001.
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DELAYED-TYPE HYPERSENSITIVITY
Despite the fact that the peritoneal recruitment assay led to
enhanced recruitment, we tested the anti-inflammatory poten-
tial of the sulfated GAG analogs in another model, delayed-type
hypersensitivity. Initial experiments were performed in order to
define the optimal dose and the regimen for the administra-
tion of MHxS. A dose-response experiment using 0.1, 1, and
10mg/kg (dosing at −30min and at +8 h post-challenge) was
performed and statistically significant inhibitions were shown
only for the highest dose (data not shown). In a subsequent exper-
iment we tested whether we could alter the efficacy of MHxS
in this model by varying the frequency of administrations while
keeping the same dose of 10mg/kg. We concluded that while the
pre-administration of MHxS at −30min was important for the
observed effect, the administration of a pre-treatment dose 24 h
before challenge on top of the dosings performed at −30min
and at +8 h did not further improve the inhibition in paw
thickness-induced by MHxS. Finally, a head to head compari-
son of the efficacy of NisS, StachS, and MHxS was performed at
the best conditions defined in earlier experiments, i.e., fixed dose
of 10mg/kg with compounds being administered at −30min
and +8 h post-challenge. These results are shown in Figure 5,
where paw swelling was inhibited by treatment with NisS, StachS,
and MHxS by an order of 20, 41, and 39% respectively in
comparison to 47% for dexamethasone.
ANTIGEN-INDUCED ARTHRITIS MODEL
The sulfated GAG compounds also displayed anti-inflammatory
properties in mBSA-immunized mice, a rodent model for
arthritis. We found a statistically significant reduction of
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FIGURE 5 | Inhibition of delayed-type hypersensitivity. Immunization
was performed by s.c. administration of SRBC, followed by a challenge in
the hindpaw 5 days later. The persulfated oligosaccharides (10mg/kg) were
administered 30min prior and 8 h after the challenge. Dexamethasone was
used as a positive control, and paw thickness was measured 21h following
the challenge. The statistical differences vs. the control group (mice
challenged with SRBC and treated with vehicle for the compounds 0.02%
BSA diluted in PBS) are shown whenever present and indicated by
∗P < 0.05; ∗∗∗P < 0.001.
neutrophil and mononuclear cell recruitment into the knee cav-
ity after treatment with MHxS or NisS, and a reduction of
mononuclear cells after treatment with heparin (Figure 6).
DISCUSSION
We have described two approaches for the generation of
molecules with potential anti-inflammatory activity as a sub-
stitute for heparin. In the first approach, we linked two
small molecules that were identified by NMR screening and
X-ray crystallography to bind to two separate sites on the
chemokine CCL5 to form a chimera with potentially more potent
inhibitory activity than the separate molecules. In the second
approach, we persulfated commercially available short carbo-
hydrates in order to obtain sulfated GAG analogs with the
anti-inflammatory properties of heparin but lacking the anti-
coagulant activity.
Molecule 1 (Figure 1A) presents the first small molecule
described to inhibit the interaction of CCL5 with heparin with
an IC50 of 320μM, and is also able to prevent the interaction of
CCL5 with the receptor CCR1. This molecule was capable of pre-
venting the recruitment of leukocytes to the peritoneum of the
mouse, with an EC50 of 0.06μg/ mouse. Molecule 2 was iden-
tified from the NMR screen, and so would be expected to have
a similar affinity for CCL5. Direct measurement of the affin-
ity was not possible because the protein complex precipitated.
Molecule 2 was found to bind to CCL5 from the X-ray crystal-
lographic structure, but at a different site, closer to the dimer
interface. Based on the identification of these two different bind-
ing sites, Molecule 3 was synthesized, which contains the key
active functional groups of Molecules 1 and 2, with an appro-
priate spacer. However, we were not able to demonstrate a more
potent inhibition of these interactions with Molecule 3. We were
not able to measure an interaction constant for Molecule 3 with
CCL5, due to the precipitation issues. There was an encourag-
ing signal in the CCR1 binding assay, where Molecule 3 showed
a 3-fold tighter interaction than Molecule 1. In vivo, however,
there was no inhibition of recruitment, rather an enhancement
at the highest dose. Our working hypothesis is that Molecule 3 is
able to crosslink CCL5 molecules, thereby forming higher order
oligomers of CCL5, which are known to be responsible for the
activity in the murine model (Proudfoot et al., 2003). Since CCL5
exists under physiological conditions as an oligomer (Bruhl et al.,
2001) the precise molecular interaction of Molecule 3 would
either have to stabilize the active conformation, or provide addi-
tional affinity sites, in order to have a biological effect. The
difficulty of predicting the in vivo activity of compounds from
the in vitro data and structural analysis suggested that this line
of investigation was unlikely to generate a therapeutically useful
molecule.
In the search for anti-inflammatory compounds which would
block the chemokine GAG interaction, we performed the study
on persulfated GAG analogs. These analogs were chosen based
on the length, since anything longer than six saccharides proved
impossible to study in the structural and biochemical assays, and
anything shorter than four saccharides lacked sufficient potency
for meaningful biological studies. All three persulfated com-
pounds showed weak micromolar activity in the inhibition of
www.frontiersin.org October 2012 | Volume 3 | Article 293 | 9
Severin et al. GAGs as an anti-inflammatory strategy targeting chemokines
0
50
100
150
mBSA 10μg/μl/knee cavity
* *
N
um
be
r o
f T
ot
al
 c
el
ls
X
10
3 /
C
av
ity
Sham Control Heparin MHxS NisS
N
um
be
r o
f N
eu
tro
ph
ils
X
10
3 /
C
av
ity
mBSA 10μg/μl/knee cavity
Sham Control Heparin MHxS NisS
0
20
40
60
80
* *
N
um
be
r o
f M
on
on
uc
le
ar
 c
el
ls
X
10
3 /
C
av
ity
mBSA 10μg/μl/knee cavity
Sham Control Heparin MHxS NisS
0
25
50
75
100
125
*
*
*
A B C
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heparin binding, but showed sub-micromolar activity in block-
ing CCR1 binding, and an order of magnitude more potent
in blocking CCR5. However, MHxS also enhanced recruit-
ment in the peritoneal recruitment assay, as was observed for
Molecule 3.
The role of GAG binding was first demonstrated to be
essential for the activity of chemokine-induced cell migration
in vivo (Proudfoot et al., 2003). Recent studies have, how-
ever, shown that abrogation of GAG binding can result in an
increased cellular recruitment in certain tissues (Tanino et al.,
2010). Although mice lack CXCL8, the human chemokine is
capable of inducing neutrophil recruitment in mice; mutants
of CXCL8 which have lost their capacity to bind to heparin,
nonetheless recruit more neutrophils than the wild type pro-
tein when instiled into the lungs. It was also observed that
recruitment-induced by the murine neutrophil CXC chemoat-
tractants KC and MIP-2 gave different results, with KC being
the most efficient, despite the fact that surface plasmon reso-
nance had demonstrated that KC associated and dissociated more
rapidly from surface bound heparin. These data suggest that
the relationship between chemokines and cell surface GAGs is
in fact more complex than initially suspected, and will require
a more thorough investigation of this biology, particularly in
view of targeting this axis as a possible anti-inflammatory strat-
egy. Interestingly it has recently been shown that GAGs can also
show opposing effects in vitro, where CXCL8 mediated chemo-
taxis was inhibited by heparin but induction of reactive oxygen
species was enhanced by several GAG families (Schlorke et al.,
2012).
Despite the conflicting results in the simple in vivo model
of peritoneal cellular recruitment, we subsequently tested the
GAG analogs in two other in vivo models of inflammation.
The first model was a delayed-type hypersensitivity model in
mice immunized with sheep red blood cells, and the second
was an antigen-induced arthritis model where mice were immu-
nized with mBSA. In both of these models, we could demon-
strate a beneficial effect of the sulfated oligosaccharides. In the
DTH model MHxS and StachS showed a comparable effect on
the reduction of paw thickness as dexamethasone which was
used as a control treatment (Figure 6). In the mBSA-induced
arthritis model both MHxS and NisS reduced the recruitment
of neutrophils and mononuclear cells to the knee cavity, whereas
heparin only had an effect on the recruitment of mononuclear
cells (Figure 6).
It remains to be elucidated why these compounds have an
anti-inflammatory effect in these two models, but an apparent
pro-inflammatory effect in the simple peritoneal recruitment
assay. There are some differences in these models that could con-
tribute to these contradictory effects. The peritoneal recruitment
assay is performed in naïve mice, whereas for the DTH and AIA
models the mice are previously immunized. This implies that
in these models the immune response is elicited by the adap-
tive immune system, whereas in peritoneal recruitment it is a
response of the innate system. It should also be noted that the
CXCL12 binder showed inhibition of the inflammatory infil-
trate in an allergic airway inflammation model of, again a model
elicited by the adaptive immune system (Hachet-Haas et al.,
2008).
To support the idea of searching for novel compounds that
interfere with the chemokine-GAG axis, it should not be forgot-
ten that heparin has been used as an anti-coagulant in the clinic
for decades and a pro-inflammatory effect has never been docu-
mented. Since heparin also causes increased recruitment into the
peritoneal cavity, we could conclude that this is a peculiarity of
this compartment.
In conclusion, we have demonstrated that the identification
of compounds interfering with chemokine-GAG binding is pos-
sible. These compounds display anti-inflammatory activity, but
further work will be required to unravel the mechanism of action
that provides both the pro-inflammatory and anti-inflammatory
effects in vivo. The inhibitory effect of the compounds under
inflamed conditions could be attributed to several mechanisms,
but predominantly to disruption of the chemokine-GAG interac-
tion. Further work should be undertaken to determine the affinity
of the compounds to GAGs expressed in the physiological con-
text, such as heparan sulphate, dermatan sulphate, or chondroitin
sulphate. However, other mechanisms could play a role such as
inhibition of CCR1 mediated recruitment or possible prevention
of the formation of oligomeric states of the chemokine which have
been shown to be essential for cellular recruitment mediated by
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certain chemokines in vivo (Proudfoot et al., 2003). Lastly,
since the oligosaccharide family provides the highest diversity
among biological macromolecules (Shriver et al., 2002), pro-
viding a wealth of possible structures, these compounds could
potentially provide a novel class of therapeutics and the concept
of GAG mimetics has in fact been explored for the inhibition of
chemokine-induced metastasis (Sutton et al., 2007; Friand et al.,
2009).
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